• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
【24h】

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

机译：长效注射利培酮治疗精神分裂症：第一个长效第二代抗精神病药的12个月开放标签试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia. METHOD: After a 2-week run-in period during which patients with DSM-IV schizophrenia received flexible doses of 1 to 6 mg of oral risperidone, patients received injections of 25 mg, 50 mg, or 75 mg of long-acting risperidone every 2 weeks for 12 months. Severity of extrapyramidal symptoms was assessed with the Extrapyramidal Symptom Rating Scale (ESRS), and efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS). This study was conducted from March 29, 1999 to July 19, 2000. RESULTS: The subjects were 615 patients with schizophrenia who received at least 1 injection of long-acting risperidone. The 12-month trial was completed by 65% of patients. Treatment was discontinued because of adverse events in 5% of patients. Extrapyramidal symptoms as adverse events were reported by 25% of the patients. Severity of extrapyramidal symptoms (according to ESRS scores) was low at baseline and decreased in each of the groups during the 12 months. The other most common adverse events were anxiety in 24%, insomnia in 21%, psychosis in 17%, and depression in 14% of the patients. Little pain was associated with the injections. Severity of symptoms of schizophrenia was improved in each group, with significant reductions in PANSS total scores (p <.01) and positive (p <.01) and negative (p <.001) factor scores. CONCLUSION: In terms of both safety and efficacy, symptomatically stable patients with schizophrenia benefit from being switched to long-acting injectable risperidone.
机译：背景：在稳定的精神分裂症患者中评估了长效可注射利培酮（第一种长效第二代抗精神病药）的长期安全性和有效性。方法：在为期2周的DSM-IV精神分裂症患者接受1到6 mg口服利培酮柔性剂量的磨合期后，患者每次注射25 mg，50 mg或75 mg长效利培酮2周，共12个月。锥体外系症状的严重程度通过锥体外系症状评定量表（ESRS）进行评估，疗效通过阳性和阴性综合征量表（PANSS）进行评估。该研究于1999年3月29日至2000年7月19日进行。结果：受试者为615例精神分裂症患者，他们接受了至少1剂长效利培酮注射。这项为期12个月的试验由65％的患者完成。由于5％的患者发生不良事件而终止治疗。 25％的患者报告了锥体外系症状为不良事件。锥体束外症状的严重程度（根据ESRS评分）在基线时很低，并且在12个月中每个组中都降低了。其他最常见的不良事件是：焦虑症的患者为24％，失眠的患者为21％，精神病的患者为17％，抑郁症的患者为14％。注射几乎没有痛苦。每组的精神分裂症症状严重程度均得到改善，PANSS总分（p <.01），阳性（p <.01）和阴性（p <.001）因子得分显着降低。结论：从安全性和有效性来看，症状稳定的精神分裂症患者可改用长效注射利培酮。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号